drugset / Trial / NCT00636883
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of Gemcitabine, Oxaliplatin and Erlotinib in the treatment of patients with pancreatic cancer will provide increased clinical benefits and improvement in their quality of life.
Timeline
- Start
- 2008-01
- Primary completion
- 2012-07
- Completion
- 2012-07
Outcome
Outcome not reported
Stopped (Enrollment): “slow accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |